MX2018010218A - Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de fibrosis. - Google Patents

Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de fibrosis.

Info

Publication number
MX2018010218A
MX2018010218A MX2018010218A MX2018010218A MX2018010218A MX 2018010218 A MX2018010218 A MX 2018010218A MX 2018010218 A MX2018010218 A MX 2018010218A MX 2018010218 A MX2018010218 A MX 2018010218A MX 2018010218 A MX2018010218 A MX 2018010218A
Authority
MX
Mexico
Prior art keywords
diseases
treatment
pharmaceutical compositions
fibrosis
novel compounds
Prior art date
Application number
MX2018010218A
Other languages
English (en)
Inventor
Jeanne Marie Menet Christel
Mammoliti Oscar
Allart Brigitte
Karel Jansen Koen
Marie Elise Palisse Adeline
Martine Andrée- Marie Joannesse Caroline
El Bkassiny Sandy
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2018010218A publication Critical patent/MX2018010218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención describe compuestos de acuerdo con la Fórmula I: (ver Fórmula) en donde R1a, R1b R2a, R2b, R3, R4, R5, R6a, X, Cy1, Cy2, y los subíndices n y m son como se define en la presente. La presente invención se refiere a compuestos antagonistas del receptor de 1-fosfato de esfingosina (S1P), métodos para su producción, composiciones farmacéuticas que los comprenden, y métodos de tratamiento en los que se usan, para la profilaxis y/o el tratamiento de enfermedades que involucran enfermedades fibróticas, enfermedades inflamatorias, enfermedades autoinmunes, enfermedades metabólicas, enfermedades cardiovasculares y/o enfermedades proliferativas mediante la administración del compuesto de la invención.
MX2018010218A 2016-03-04 2017-02-23 Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de fibrosis. MX2018010218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603745.9A GB201603745D0 (en) 2016-03-04 2016-03-04 Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
PCT/EP2017/054139 WO2017148787A1 (en) 2016-03-04 2017-02-23 Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
MX2018010218A true MX2018010218A (es) 2018-11-09

Family

ID=55858990

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010218A MX2018010218A (es) 2016-03-04 2017-02-23 Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de fibrosis.

Country Status (19)

Country Link
US (1) US20190388421A1 (es)
EP (1) EP3423445B1 (es)
JP (1) JP2019507766A (es)
KR (1) KR20180118752A (es)
CN (1) CN108699037A (es)
AR (1) AR107798A1 (es)
AU (1) AU2017227900A1 (es)
BR (1) BR112018067312A2 (es)
CA (1) CA3016185A1 (es)
CO (1) CO2018009876A2 (es)
GB (1) GB201603745D0 (es)
IL (1) IL261444A (es)
MX (1) MX2018010218A (es)
PH (1) PH12018501849A1 (es)
RU (1) RU2018134780A (es)
SG (1) SG11201807540UA (es)
TW (1) TW201734005A (es)
WO (1) WO2017148787A1 (es)
ZA (1) ZA201805601B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210038502A1 (en) 2017-11-08 2021-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) S1pr2 antagonists for treating diseases involving abnormal immune responses
CA3082742A1 (en) 2017-11-15 2019-05-23 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
WO2019148851A1 (zh) * 2018-02-02 2019-08-08 青岛清原化合物有限公司 五元环取代的哒嗪醇类化合物及其衍生物、制备方法、除草组合物和应用
CN110878086B (zh) * 2018-09-06 2024-06-07 青岛清原化合物有限公司 五元环取代的哒嗪醇类化合物及其衍生物、制备方法、除草组合物和应用
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用
CN110128457B (zh) * 2019-05-24 2022-05-03 宁波瑞奇医药科技有限公司 杂环小分子化合物的制备方法
US11465982B2 (en) * 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
US11485727B2 (en) * 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
WO2023069721A2 (en) * 2021-10-22 2023-04-27 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760174B2 (en) * 1999-02-09 2003-05-08 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
WO2009042485A1 (en) * 2007-09-24 2009-04-02 Allergan, Inc. Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity

Also Published As

Publication number Publication date
CA3016185A1 (en) 2017-09-08
WO2017148787A1 (en) 2017-09-08
EP3423445A1 (en) 2019-01-09
KR20180118752A (ko) 2018-10-31
CO2018009876A2 (es) 2018-10-10
SG11201807540UA (en) 2018-09-27
US20190388421A1 (en) 2019-12-26
AR107798A1 (es) 2018-06-06
ZA201805601B (en) 2019-06-26
RU2018134780A (ru) 2020-04-06
CN108699037A (zh) 2018-10-23
PH12018501849A1 (en) 2019-01-28
AU2017227900A1 (en) 2018-10-25
EP3423445B1 (en) 2020-04-01
IL261444A (en) 2018-10-31
BR112018067312A2 (pt) 2018-12-26
JP2019507766A (ja) 2019-03-22
GB201603745D0 (en) 2016-04-20
TW201734005A (zh) 2017-10-01

Similar Documents

Publication Publication Date Title
PH12018501849A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
MX2019015350A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MD20150091A2 (ro) Compuşi antivirali
SG10201808624VA (en) Polymorphs of selinexor
MX2017014035A (es) Formas solidas novedosas.
PH12018501644A1 (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
PH12017500095A1 (en) Imidazopyridazine compounds
PH12017500595A1 (en) Aldosterone synthase inhibitors
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2017016939A (es) Novedosas antagonistas 5-ht2.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX2019002166A (es) Agonistas del receptor cxcr3.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
IN2014MU00070A (es)
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.